Symptomatic hyperlactatemia in an HIV-positive patient: A case report and discussion

CMAJ. Canadian Medical Association Journal

Volumn 168, Issue 2, 2003, Pages 195-198

  Antoniou, Tony ^a,b   Weisdorf, Thea ^c   Gough, Kevin ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Health Centre at 410   (Canada)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLACTATEMIA; LABORATORY TEST; PATHOPHYSIOLOGY; PREVALENCE; SYMPTOM;

EID: 0037252234     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998;351:543-9.
2. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, et al. A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogues in human immunodeficiency virus-infected persons with CD4 cell counts < 200 per cubic millimeter. N Engl J Med 1997;337:725-33.
3. Brinkman K, Smeitink JA, Romijin JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999;354:1112-5.
4. Brinkman K, ter Hofstede HJM, Burger DM, Smeitink J, Koopmans PP. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998;12:1735-44.
5. Sundar K, Suarez M, Banogon PE, Shapiro JM. Zidovudine induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: report of two patients and review of the literature. Crit Care Med 1997;25:1425-30.
6. Bissuel F, Bruneel F, Habersetzer F, Chassard D, Cotte L, Chevalier M, et al. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy. J Intern Med 1994;235:367-42.
7. Lonergan JT, Havlir D, Barber E, Mathews WC. Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens [abstract 624]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago. Abstract available: www.retroconference.org//2001/abstracts/abstracts/abstracts/624.htm (accessed 2002 Dec 9).
8. Vrouenraets SME, Treskes M, Regez RM, Troost N, Weigel HM, Frissen PHJ, et al. Hyperlactatemia in HIV-infected patients: the role of NRTI treatment [abstract 625]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago. Abstract available: www.retroconference.org//2001/abstracts/abstracts/abstracts/625.htm (accessed 2002 Dec 9).
9. Harris M, Tesiorowski A, Montaner JSG. Screening for nucleoside-associated lactic acidosis [abstract TuPpB1233]. XIII International AIDS Conference; 2000 July 9-14; Durban, South Africa. Abstract available: www.iac2000.org/abdetail.asp?ID=TuPpB1233 (accessed 2002 Dec 9).
10. Antela A, Moreno S, Pallares E, Rubi J, Pumares M, Casado, JL, et al. Prevalence of hyperlactatemia (HL) in asymptomatic HIV-infected patients receiving nucleoside analogues (NA) and relationship with fat distribution abnormalities (FDA): a cross-sectional study [abstract I-225]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago.
11. John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 2001;15:717-23.
12. Blanco F, Laguna F, Garcia-Benayas T, Soriano V, Moreno V, Valencia E, et al. Lactate levels in HIV-positive patients under antiretroviral treatment [abstract P14]. Antivir Ther 2000;5(Suppl 5):32.
13. Boubaker K, Flepp M, Sudre P, Furrer H, Haensel A, Hirschel B, et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV cohort study. Clin Infect Dis 2001;33:1931-7.
14. McComsey GA, Yau L, Southwell H, Gripshover B, Asaad R, Valdez H, et al. Elevated lactate levels are uncommon, even in heavily pretreated HIV-infected subjects [abstract 710-T]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle. Abstract available: www.retroconference.org /2002/Abstract/13205.htm (accessed 2002 Dec 9).
15. Lonergan JT, Behling C, Pfander H, Hassanein TI, Mathews WC. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis 2000;31:162-6.
16. Gerard Y, Maulin L, Yazdanpanah Y, De La Tribonniere X, Amiel C, Maurage CA, et al. Symptomatic hyperlactataemia: an emerging complication of antiretroviral therapy. AIDS 2000;14:2723-30.
17. Delgado J, Harris M, Tesiorowski A, Montaner JSG. Symptomatic elevations of lactic acid and their response to treatment manipulation in human immunodeficiency virus-infected persons: a case series. Clin Infect Dis 2001;33:2072-4.
18. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem 2001;276:40847-57.
19. Lim SE, Copeland WC. Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J Biol Chem 2001;276:23616-23.
20. Cote HCF, Brumme ZL, Craib KJP, Alexander CS, Wynhoven B, Ting L, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002;346:811-20.
21. Chen CH, Vazquez-Padua M, Cheng YC. Effect of anti-human immunodeficiency virus nucleoside analogues on mitochondrial DNA and its implication for delayed toxicity. Mol Pharmacol 1991;39:625-8.
22. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994;38:2743-9.
23. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in pyrimidine nucleoside combinations [abstract 18]. Antivir Ther 2001;6 (Suppl 4):13-4.
24. Leclercq P, Roth H, Bosseray A, Leverve X. Investigating lactate metabolism to estimate mitochondrial status [abstract 21]. Antivir Ther 2001;6(Suppl 4):16.
25. Fortang IS, Belitsos PC, Chaisson RE, Moore RD. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy. Am J Gastroenterol 1995;90:1433-6.
26. Falco V, Rodriguez D, Ribera E, Martinez E, Miro JM, Domingo P, et al. Severe nucleoside-associated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002;34:838-46.
27. Galera C, Redondo C, Poza G, Garcia M, Gomez H, Ruiperez J, et al. Symptomatic hyperlactatemia and lactic acidosis syndrome in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors (NRTIs) [abstract 517]. 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 July 8-11; Buenos Aires. Abstract available: www.ias.se/abstract/show.asp?abstract_id=517 (accessed 2002 Dec 9).
28. Wooltorton E. HIV drug stavudine (Zerit, d4T) and symptoms mimicking Guillain-Barré syndrome. CMAJ 2002;166(8):1067.
29. Brew B, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy [abstract 9]. 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago. Abstract available: www.retroconference.org//2001/abstracts/abstracts /abstracts/9.htm (accessed 2002 Dec 9).
30. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic academia and lower weight pre-antiretroviral therapy. AIDS 2001;15:703-9.
31. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000;14:F25-32.
32. Lonergan JT, Havlir D, Barber E, Mathews WC. Incidence of symptomatic hy-perlactatemia in HIV-infected adults [abstract 35]. 9th Conference on Retroviruses and Opportunistic Infections; 2002 Feb 24-28; Seattle. Abstract available: www.retroconference.org/2002/Abstract/13202.htm (accessed 2002 Dec 9).
33. Lonergan JT, Havlir D, Barber E, Mathews WC. Hyperlactatemia associated with clinical manifestations in HIV-infected patients receiving nucleoside analogue combination regimens [abstract P20]. Antivir Ther 2000;5(Suppl 5):35-6.
34. Datta D, Morelese J, Moyle G, Asboe D, Matthews G, Mandalia S, et al. Hyperlactatemia during antiretroviral therapy: Does nucleoside analogue choice matter? [abstract 519]. 1st IAS Conference on HIV Pathogenesis and Treatment; 2001 July 8-11; Buenos Aires. Abstract available: www.ias.se/abstract/show.asp?abstract_id=519 (accessed 2002 Dec 9).
35. Moyle GJ, Datta D, Mandalia S, Morlese J, Asboe D, Gazzard BG. Hyperlactatemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 2002;16:1341-9.
36. Longergan T, McComsey G, Hessenthaler S, Shalit P, File T, Williams V, et al. Lack of recurrence of symptomatic and asymptomatic hyperlactatemia when stavudine is replaced by either abacavir or zidovudine: 48-week data. [abstract 21]. Antivir Ther 2002;7(Suppl):L13-4.
37. Birkus G, Hitchcock MJM, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002;46:716-23.
38. Brinkman K. Management of hyperlactatemia: no need for routine lactate measurements. AIDS 2001;15:795-7.
39. Johri S, Alkhuja S, Siviglia G, Soni A. Steatosislactic acidosis syndrome associated with stavudine and lamivudine therapy. AIDS 2000;14:1286-7.
40. Claessens YE, Cariou A, Chiche JD, Dauriat G, Dhainaut JF. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 2000;14:472-3.
41. Dalton SD, Rahimi AR. Emerging role of riboflavin in the treatment of nucleoside analogue-induced type B lactic acidosis. AIDS Patient Care STDS 2001;15:611-4.
42. Fouty B, Freman F, Reves R. Riboflavin to treat nucleoside analogue induced lactic acidosis. Lancet 1998;352:291-2.
43. Arici C, Tebaldi A, Quinzan GP, Maggiolo F, Ripamonti D, Suter F. Severe lactic acidosis and thiamine administration in an HIV-infected patient on HAART. Int J STD AIDS 2001;12:407-9.
44. Brinkman K, Vrouenraets S, Kauffmann R, Weigel H, Frissen J. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 2000;14:2801-2.